Platelet aggregation and hemostasis mechanisms

Platelet aggregation and hemostasis mechanisms encompass the physiological processes that prevent blood loss following vascular injury while maintaining blood fluidity (StatPearls, NBK545263). This system involves a complex interplay between the endothelium, platelets, and plasma coagulation factors. Upon vessel damage, platelets adhere to the subendothelium, undergo activation, and aggregate to form a primary plug (PubMed, NBK554424). This is followed by the secondary hemostasis phase, where the coagulation cascade generates thrombin to convert fibrinogen into a stable fibrin mesh. While essential for survival, overactivity of these mechanisms leads to arterial or venous thrombosis, contributing to life-threatening conditions such as myocardial infarction and ischemic stroke (NIH, Blood Clots). Conversely, deficiencies in these pathways result in bleeding disorders like hemophilia or von Willebrand disease. Therapeutic strategies targeting these mechanisms include antiplatelet drugs and anticoagulants, which are vital for managing cardiovascular and thromboembolic risks (PubChem, Aspirin).

Other names

HemostasisBlood coagulationPlatelet activationThrombogenesisCoagulation cascade

Inhibition of platelet activation and aggregation via various pathways (e.g., COX-1 inhibition, P2Y12 antagonism, GP IIb/IIIa antagonism, PAR-1 antagonism) and inhibition of the coagulation cascade (e.g., Factor Xa inhibition, Thrombin inhibition, Vitamin K epoxide reductase inhibition).